Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart

scientific article

Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2014PLoSO...9j1763O
P356DOI10.1371/JOURNAL.PONE.0101763
P932PMC publication ID4103775
P698PubMed publication ID25036938
P5875ResearchGate publication ID264054906

P50authorAlessandro StefaniQ56418196
Enrica OlivolaQ59564394
Paola ImbrianiQ59692808
Mario Alberto Ugo Stampanoni BassiQ85651614
Vincenza D'AngeloQ38323218
Nicola B. MercuriQ42521269
P2093author name stringMarco Conti
Claudio Liguori
Mariangela Pierantozzi
P2860cites workProgression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study.Q51160375
Depression and Parkinson's disease: possible role of serotonergic mechanismsQ68988930
Depression in Parkinson's disease: biogenic amines in CSF of "de novo" patientsQ73065148
Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaqueQ95823022
Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's diseaseQ34296780
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trialQ34619438
Brain serotonin transporter binding in non-depressed patients with Parkinson's diseaseQ34619565
Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease?Q35004662
Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PDQ37536347
The serotonergic system in Parkinson's diseaseQ37924025
The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery.Q37968025
Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.Q37973611
CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.Q38012590
Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's diseaseQ42287995
Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's choreaQ42489819
Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structuresQ42794711
Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT studyQ42952850
Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET studyQ42994792
Evidence for an association between the CSF HVA:5-HIAA ratio and aggressiveness in frontotemporal dementia but not in Alzheimer's disease.Q43068453
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.Q43675942
Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease.Q43792598
Mirtazapine in L-dopa-induced dyskinesiasQ44536093
Positron emission tomography of striatal serotonin transporters in Parkinson diseaseQ44585433
Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's diseaseQ44888788
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease.Q48095855
100 years of Lewy pathologyQ48278741
Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group.Q48413069
Altered serotonin metabolism in depressed patients with parkinson's disease.Q48680548
Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease.Q48846598
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue7
P407language of work or nameEnglishQ1860
P304page(s)e101763
P577publication date2014-07-18
P1433published inPLOS OneQ564954
P1476titleSerotonin impairment in CSF of PD patients, without an apparent clinical counterpart
P478volume9

Reverse relations

cites work (P2860)
Q61813331An Investigation on the Clinical Features and Neurochemical Changes in Parkinson's Disease With Depression
Q43122361Commentary: Clinical Correlates of Raphe Serotonergic Dysfunction in Early Parkinson's Disease.
Q46365963Cytotoxic and cytoprotective effects of tryptamine-4,5-dione on neuronal cells: a double-edged sword.
Q38639708Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson's disease.
Q64859245Does fatigue in Parkinson's disease correlate with autonomic nervous system dysfunction?
Q96953378Increased Noradrenaline as an Additional Cerebrospinal Fluid Biomarker in PSP-Like Parkinsonism
Q39105633Peripheral blood gene expression profiles linked to monoamine metabolite levels in cerebrospinal fluid.

Search more.